Skip to main content
Top
Gepubliceerd in: Quality of Life Research 2/2021

22-09-2020

Patient-reported outcomes in non-muscle invasive bladder cancer: a mixed-methods systematic review

Auteurs: Claudia Rutherford, Manish I. Patel, Margaret-Ann Tait, David P. Smith, Daniel S. J. Costa, Shomik Sengupta, Madeleine T. King

Gepubliceerd in: Quality of Life Research | Uitgave 2/2021

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Objective

Non-muscle invasive bladder cancer (NMIBC) is a chronic condition requiring repeated treatment and endoscopic examinations that can occur life-long. In this context, patient-reported outcomes (PROs) are important considerations to patients and managing clinicians. We undertook a systematic review to synthesise PRO results relevant to NMIBC treatment to explore trajectories overtime and differences between treatment options.

Methods

We searched databases AMED, MEDLINE, EMbase, PsycINFO, Web of Knowledge and Scopus (inception to 5th December 2019), reference lists and contacted key authors to identify studies that reported PROs after NMIBC treatment. Two reviewers independently applied inclusion and quality criteria and extracted findings. Results for PROs were synthesised for treatment groups across three time periods: acute/during induction therapy; during maintenance therapy; and long-term follow-up (> 1 year).

Results

Of 3193 papers screened, 29 were eligible. These provided evidence about induction treatment effects, but few reported maintenance or long-term evidence, and evidence about differences between NMIBC treatment options was lacking. A range of symptoms (pain in bladder area, urinary frequency and urgency, pain or burning during urination) were commonly experienced during and soon after treatment for NMIBC. Less common symptoms included fatigue, disrupted sleep and gastrointestinal problems.

Conclusions

Treatments for NMIBC can cause symptoms and functional impairment during the acute treatment phase and reduce quality of life. Clinicians should be aware of these impairments to prepare patients for short-term sequelae and enable those with treatment options to exercise preferences in choosing among them. However, gaps in current evidence limit our understanding of PRO trajectories from diagnosis through to long-term survivorship and treatment effects.
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
1.
go back to reference Cheluvappa, R., Smith, D. P., Cerimagic, S., & Patel, M. I. (2014). A comprehensive evaluation of bladder cancer epidemiology and outcomes in Australia. International Urology and Nephrology, 46(7), 1351–1360.CrossRef Cheluvappa, R., Smith, D. P., Cerimagic, S., & Patel, M. I. (2014). A comprehensive evaluation of bladder cancer epidemiology and outcomes in Australia. International Urology and Nephrology, 46(7), 1351–1360.CrossRef
2.
go back to reference Heney, N. M. (1992). Natural history of superficial bladder cancer Prognostic features and long-term disease course. Urologic Clinics of North America, 19(3), 429–433. Heney, N. M. (1992). Natural history of superficial bladder cancer Prognostic features and long-term disease course. Urologic Clinics of North America, 19(3), 429–433.
4.
go back to reference US Department of Health & Human Support Food & Drug Administration. (2009). Patient reported outcome measures: Use in medical product development to support labelling claims. MD: US Department of Health & Human Support Food & Drug Administration. US Department of Health & Human Support Food & Drug Administration. (2009). Patient reported outcome measures: Use in medical product development to support labelling claims. MD: US Department of Health & Human Support Food & Drug Administration.
8.
9.
go back to reference Botteman, M. F., Pashos, C. L., Hauser, R. S., Laskin, B. L., & Redaelli, A. (2003). Quality of life aspects of bladder cancer: a review of the literature. Quality of Life Research, 12(6), 675–688.CrossRef Botteman, M. F., Pashos, C. L., Hauser, R. S., Laskin, B. L., & Redaelli, A. (2003). Quality of life aspects of bladder cancer: a review of the literature. Quality of Life Research, 12(6), 675–688.CrossRef
11.
go back to reference Kmet, L., Lee, R., Cook, L., & Alberta Heritage Foundation for Medical Research. (2004). Standard quality assessment criteria for evaluating primary research papers from a variety of fields. Edmonton: Alta Alberta Heritage Foundation for Medical Research. Kmet, L., Lee, R., Cook, L., & Alberta Heritage Foundation for Medical Research. (2004). Standard quality assessment criteria for evaluating primary research papers from a variety of fields. Edmonton: Alta Alberta Heritage Foundation for Medical Research.
13.
go back to reference Colombo, R., Rocchini, L., Suardi, N., Benigni, F., Colciago, G., Bettiga, A., et al. (2012). Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study. European Urology, 62(5), 797–802. https://doi.org/10.1016/j.eururo.2012.05.032.CrossRefPubMed Colombo, R., Rocchini, L., Suardi, N., Benigni, F., Colciago, G., Bettiga, A., et al. (2012). Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study. European Urology, 62(5), 797–802. https://​doi.​org/​10.​1016/​j.​eururo.​2012.​05.​032.CrossRefPubMed
14.
15.
go back to reference Mack, D., & Frick, J. (1996). Quality of life in patients undergoing bacille Calmette-Guerin therapy for superficial bladder cancer. British Journal of Urology, 78(3), 369–371.CrossRef Mack, D., & Frick, J. (1996). Quality of life in patients undergoing bacille Calmette-Guerin therapy for superficial bladder cancer. British Journal of Urology, 78(3), 369–371.CrossRef
16.
go back to reference Steinberg, R. L., Thomas, L. J., Mott, S. L., O'Donnell, M., & A., (2019). Multi-perspective tolerance evaluation of bacillus calmette-guerin with interferon in the treatment of non-muscle invasive bladder cancer. Bladder Cancer, 5(1), 39–49. https://doi.org/10.3233/BLC-180203.CrossRef Steinberg, R. L., Thomas, L. J., Mott, S. L., O'Donnell, M., & A., (2019). Multi-perspective tolerance evaluation of bacillus calmette-guerin with interferon in the treatment of non-muscle invasive bladder cancer. Bladder Cancer, 5(1), 39–49. https://​doi.​org/​10.​3233/​BLC-180203.CrossRef
17.
go back to reference Gontero, P., Oderda, M., Mehnert, A., Gurioli, A., Marson, F., Lucca, I., et al. (2013). The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guerin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial. Journal of Urology, 190(3), 857–862.CrossRef Gontero, P., Oderda, M., Mehnert, A., Gurioli, A., Marson, F., Lucca, I., et al. (2013). The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guerin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial. Journal of Urology, 190(3), 857–862.CrossRef
18.
go back to reference Krajewski, W., Koscielska-Kasprzak, K., Rymaszewska, J., & Zdrojowy, R. (2017). How different cystoscopy methods influence patient sexual satisfaction, anxiety, and depression levels: a randomized prospective trial. Quality of Life Research. Krajewski, W., Koscielska-Kasprzak, K., Rymaszewska, J., & Zdrojowy, R. (2017). How different cystoscopy methods influence patient sexual satisfaction, anxiety, and depression levels: a randomized prospective trial. Quality of Life Research.
20.
go back to reference Yokomizo, A., Kanimoto, Y., Okamura, T., Ozono, S., Koga, H., Iwamura, M., et al. (2016). Randomized Controlled Study of the Efficacy, Safety and Quality of Life with Low Dose bacillus Calmette-Guerin Instillation Therapy for Nonmuscle Invasive Bladder Cancer. Journal of Urology, 195(1), 41–46. https://doi.org/10.1016/j.juro.2015.08.075.CrossRef Yokomizo, A., Kanimoto, Y., Okamura, T., Ozono, S., Koga, H., Iwamura, M., et al. (2016). Randomized Controlled Study of the Efficacy, Safety and Quality of Life with Low Dose bacillus Calmette-Guerin Instillation Therapy for Nonmuscle Invasive Bladder Cancer. Journal of Urology, 195(1), 41–46. https://​doi.​org/​10.​1016/​j.​juro.​2015.​08.​075.CrossRef
22.
go back to reference Smith, A. B., Daneshmand, S., Patel, S., Pohar, K., Trabulsi, E., Woods, M., et al. (2019). Patient-reported outcomes of blue-light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: results from a prospective multicentre study. BJU International, 123(1), 35–41. https://doi.org/10.1111/bju.14481.CrossRefPubMed Smith, A. B., Daneshmand, S., Patel, S., Pohar, K., Trabulsi, E., Woods, M., et al. (2019). Patient-reported outcomes of blue-light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: results from a prospective multicentre study. BJU International, 123(1), 35–41. https://​doi.​org/​10.​1111/​bju.​14481.CrossRefPubMed
25.
go back to reference Bohle, A., Balck, F., von Weitersheim, J., & Jocham, D. (1996). The quality of life during intravesical bacillus Calmette-Guerin therapy. Journal of Urology, 155(4), 1221–1226.CrossRef Bohle, A., Balck, F., von Weitersheim, J., & Jocham, D. (1996). The quality of life during intravesical bacillus Calmette-Guerin therapy. Journal of Urology, 155(4), 1221–1226.CrossRef
32.
go back to reference Yoshimura, K., Utsunomiya, N., Ichioka, K., Matsui, Y., Terai, A., & Arai, Y. (2005). Impact of superficial bladder cancer and transurethral resection on general health-related quality of life: an SF-36 survey. Urology, 65(2), 290–294.CrossRef Yoshimura, K., Utsunomiya, N., Ichioka, K., Matsui, Y., Terai, A., & Arai, Y. (2005). Impact of superficial bladder cancer and transurethral resection on general health-related quality of life: an SF-36 survey. Urology, 65(2), 290–294.CrossRef
36.
go back to reference Hinojosa-Lindsey, M. (2011). Understanding treatment-related symptoms, symptom management techniques, and symptom management self-efficacy in a sample of non-muscle invasive bladder cancer patients. Dissertation Abstracts International Section B The Sciences and Engineering, 72(1), 214. Hinojosa-Lindsey, M. (2011). Understanding treatment-related symptoms, symptom management techniques, and symptom management self-efficacy in a sample of non-muscle invasive bladder cancer patients. Dissertation Abstracts International Section B The Sciences and Engineering, 72(1), 214.
37.
go back to reference Koo, K., Zubkoff, L., Sirovich, B., River, W., Seigne, J., Goodney, P., et al. (2017). The burden of cystoscopic bladder cancer surveillance-anxiety, discomfort, and patient preferences for decision making. Journal of Urology, 197(4), e123. Koo, K., Zubkoff, L., Sirovich, B., River, W., Seigne, J., Goodney, P., et al. (2017). The burden of cystoscopic bladder cancer surveillance-anxiety, discomfort, and patient preferences for decision making. Journal of Urology, 197(4), e123.
42.
go back to reference Brenner, M. H., Curbow, B., & Legro, M. W. (1995). The proximal-distal continuum of multiple health outcome measures: the case of cataract surgery. Medical Care, 33(4), 236–244. Brenner, M. H., Curbow, B., & Legro, M. W. (1995). The proximal-distal continuum of multiple health outcome measures: the case of cataract surgery. Medical Care, 33(4), 236–244.
43.
44.
go back to reference Lamm, D. L., Blumenstein, B. A., Crissman, J. D., Montie, J. E., Gottesman, J. E., Lowe, B. A., et al. (2000). Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. Journal of Urology, 163(4), 1124–1129.CrossRef Lamm, D. L., Blumenstein, B. A., Crissman, J. D., Montie, J. E., Gottesman, J. E., Lowe, B. A., et al. (2000). Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. Journal of Urology, 163(4), 1124–1129.CrossRef
45.
go back to reference Brausi, M., Oddens, J., Sylvester, R., Bono, A., van de Beek, C., van Andel, G., et al. (2014). Side effects of Bacillus Calmette-Guerin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. European Urology, 65(1), 69–76.CrossRef Brausi, M., Oddens, J., Sylvester, R., Bono, A., van de Beek, C., van Andel, G., et al. (2014). Side effects of Bacillus Calmette-Guerin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. European Urology, 65(1), 69–76.CrossRef
46.
go back to reference Mercieca-Bebber, R. L., Price, M. A., Bell, M. L., King, M. T., Webb, P. M., Butow, P. N., et al. (2017). Ovarian cancer study dropouts had worse health-related quality of life and psychosocial symptoms at baseline and over time. Asia-Pacific Journal of Clinical Oncology, 13(5), e381–e388. https://doi.org/10.1111/ajco.12580.CrossRefPubMed Mercieca-Bebber, R. L., Price, M. A., Bell, M. L., King, M. T., Webb, P. M., Butow, P. N., et al. (2017). Ovarian cancer study dropouts had worse health-related quality of life and psychosocial symptoms at baseline and over time. Asia-Pacific Journal of Clinical Oncology, 13(5), e381–e388. https://​doi.​org/​10.​1111/​ajco.​12580.CrossRefPubMed
49.
Metagegevens
Titel
Patient-reported outcomes in non-muscle invasive bladder cancer: a mixed-methods systematic review
Auteurs
Claudia Rutherford
Manish I. Patel
Margaret-Ann Tait
David P. Smith
Daniel S. J. Costa
Shomik Sengupta
Madeleine T. King
Publicatiedatum
22-09-2020
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 2/2021
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-020-02637-9

Andere artikelen Uitgave 2/2021

Quality of Life Research 2/2021 Naar de uitgave